Levels of cholesteryl esters and other lipids in the plasma of patients with end-stage renal failure

被引:14
作者
Gillett, MPT [1 ]
Obineche, EN [1 ]
Lakhani, MS [1 ]
Abdulle, AM [1 ]
Amirlak, I [1 ]
Al Rukhaimi, M [1 ]
Suleiman, MN [1 ]
机构
[1] UAE Univ, Dept Biochem, FMHS, Al Ain, Abu Dhabi, U Arab Emirates
关键词
plasma lipids; cholesteryl esters; chronic renal failure; lecithin-cholesterol acyltransferase;
D O I
10.5144/0256-4947.2001.283
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The importance of plasma lipid abnormalities in chronic renal failure (CRF) is well recognized, but surprisingly little attention has been given to the study of some plasma lipid fractions, including cholesteryl esters (CE) and phospholipids, which might be expected to be important factors in the pathogenesis of the disease. Materials and Methods: Fasting blood samples were taken from 25 control subjects and 53 CRF patients (29 predialysis and 24 on hemodialysis). Samples were analyzed for urea nitrogen, creatinine, triacylglycerols, total and individual phospholipids, total and free cholesterol, as well as cholesterol bound to very low-, low- and high-density lipoproteins (VLDL, LDL and HDL). Plasma CE was calculated and expressed as a percentage of total cholesterol. Results: Over half of the patients had CE levels more than two standard deviations below the control value. In this subgroup of low CE patients, total, LDL- and HDL-cholesterol levels were also significantly lower than for controls, while levels of phosphatidylcholine and lysophosphatidylcholine were decreased and increased, respectively. In patients with high CE, no significant lipid abnormalities were observed. Conclusion: In this study, CE was an excellent marker for lipid disturbances-if CE was high, then the other lipid fractions were normal, but if CE was low, most other lipid fractions were abnormal. The changes noted appear to be consequences of or related to deficiency of the plasma enzyme lecithin-cholesterol acyltransferase.
引用
收藏
页码:283 / 286
页数:4
相关论文
共 34 条
[1]   LIPOPROTEIN METABOLISM AND RENAL-FAILURE [J].
ATTMAN, PO ;
SAMUELSSON, O ;
ALAUPOVIC, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (06) :573-592
[2]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[3]   LECITHIN - CHOLESTEROL ACYLTRANSFERASE ACTIVITY IN DIALYZED AND UNDIALYZED CHRONIC UREMIC PATIENTS [J].
BORIES, PC ;
SUBBAIAH, PV ;
BAGDADE, JD .
NEPHRON, 1982, 32 (01) :22-27
[4]  
BRUNTON C, 1999, KIDNEY INT S71, V56, pS134
[5]   PLASMA LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVITIES IN UREMIC PATIENTS [J].
CHAN, MK ;
RAMDIAL, L ;
VARGHESE, Z ;
PERSAUD, JW ;
BAILLOD, RA ;
MOORHEAD, JF .
CLINICA CHIMICA ACTA, 1982, 119 (1-2) :65-72
[6]   Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small dense low-density lipoprotein formation [J].
Deighan, CJ ;
Caslake, MJ ;
McConnell, M ;
Boulton-Jones, JM ;
Packard, CJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (05) :852-862
[7]   PLASMA-CHOLESTEROL METABOLISM IN END-STAGE RENAL-DISEASE - DIFFERENCE BETWEEN TREATMENT BY HEMODIALYSIS OR PERITONEAL-DIALYSIS [J].
DIEPLINGER, H ;
SCHOENFELD, PY ;
FIELDING, CJ .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (04) :1071-1083
[8]   HYPERLIPIDEMIA IN RENAL-TRANSPLANTATION - RISK FACTOR FOR LONG-TERM GRAFT OUTCOME [J].
DIMENY, E ;
WAHLBERG, J ;
LITHELL, H ;
FELLSTROM, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1995, 25 (08) :574-583
[9]   Effect of lipid reduction on the progression of renal disease: A meta-analysis [J].
Fried, LF ;
Orchard, TJ ;
Kasiske, BL .
KIDNEY INTERNATIONAL, 2001, 59 (01) :260-269
[10]   Atherogenic lipoproteins, oxidative stress, and cell death [J].
Galle, J ;
Heermeier, K ;
Wanner, C .
KIDNEY INTERNATIONAL, 1999, 56 :S62-S65